$3.65
+0.23 (+6.73%)
Open$3.51
Previous Close$3.42
Day High$3.68
Day Low$3.45
52W High$4.22
52W Low$0.61
Volume—
Avg Volume180.5K
Market Cap204.13M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+158.1% upside
Current
$3.65
$3.65
Target
$9.42
$9.42
$6.99
$9.42 avg
$10.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.26M | 132.26M | 127.36M |
| Net Income | -84,049,736 | 2.80M | 2.65M |
| Profit Margin | -819.6% | 2.1% | 2.1% |
| EBITDA | -82,606,543 | 4.42M | 4.16M |
| Free Cash Flow | — | 2.17M | 2.21M |
| Rev Growth | — | +3.8% | -1.6% |
| Debt/Equity | — | 0.63 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |